Antimicrobial Stewardship Programs Must Apply to All

Santos, Rodrigo Pires dos; Magedanz, Lucas; Siliprandi, Erci Maria Onzi

doi:10.1086/593209

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This requires sustained effort and commitment not just from the immediate stakeholders (e.g. infectious diseases physicians, microbiologists, infection control personnel) but from a larger pool of healthcare workers [23,24]. The key areas that we identify in this review in order to overcome the barriers in the way of antimicrobial stewardship include the need for cooperation between hospital departments (e.g.…”

Section: Resultsmentioning

confidence: 99%

Antibiotic stewardship

Bal

Gould

2011

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Antibiotic stewardship

Bal

Gould

2011

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

Antimicrobial Stewardship: There's No Such Thing as Too Much

Pagani¹

2010

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin

et al. 2012

View full text Add to dashboard Cite

BackgroundSwitch therapy is a management approach combining early discontinuation of intravenous (IV) antibiotics, switch to oral antibiotics, and early hospital discharge. This analysis compares switch therapy using tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia (CAP).MethodsA prospective, randomized, double-blind, Phase 3 clinical trial; patients were randomized to IV tigecycline (100 mg, then 50 mg q12h) or IV levofloxacin (500 mg q24h). Objective criteria were used to define time to switch therapy; patients were switched to oral levofloxacin after ≥6 IV doses if criteria met. Switch therapy outcomes were assessed within the clinically evaluable (CE) population.ResultsIn the CE population, 138 patients were treated with IV tigecycline and 156 were treated with IV levofloxacin. The proportion of the population that met switch therapy criteria was 67.4% (93/138) for tigecycline and 66.7% (104/156) for levofloxacin. The proportion that actually switched to oral therapy was 89.9% (124/138) for tigecycline and 87.8% (137/156) for levofloxacin. Median time to actual switch therapy was 5.0 days each for tigecycline and levofloxacin. Clinical cure rates for patients who switched were 96.8% for tigecycline and 95.6% for levofloxacin. Corresponding cure rates for those that met switch criteria were 95.7% for tigecycline and 92.3% for levofloxacin.ConclusionsSwitch therapy outcomes in hospitalized patients with CAP receiving initial IV therapy with tigecycline are comparable to those of patients receiving initial IV therapy with levofloxacin. These data support the use of IV tigecycline in hospitalized patients with CAP when the switch therapy approach is considered.ClinicalTrials.gov IdentifierNCT00081575

show abstract

Antimicrobial Stewardship Programs Must Apply to All

Cited by 3 publications

References 12 publications

Antibiotic stewardship

Antibiotic stewardship

Antimicrobial Stewardship: There's No Such Thing as Too Much

Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin

Contact Info

Product

Resources

About